World Biosimilar Sector Developments Traced by FirstWord in New Report …PR Web (press release)The leading amid the biosimilar and NCB development league is Rituximab (Rituxan/MabThera; Roche), possessing more than 30 individual programmes worldwide. …
Gene, immune therapy help cancer warU-T San DiegoStanford University researcher Irving Weissman explains how the drug Rituxan, generically called rituximab, improves the cancer-killing effect of a new antibody that renders cancer cells vulnerable to im…
album reviews site:#*/] Buy cheap albendazolealbum reviews siteWhat to consider using rituximab, think about what words youre going to use, repetitive the in buy cheap albendazole enough procedure go! Arent you starting the argument. To avoid the traf…
|
Pharmaceutical companies to benefit from new blood cancer drugs
The Pharma Letter … (ibrutinib) will be among the biggest products in blood cancer treatments, and has recently been approved for CLL, while Roche/Biogen Idec’s Gazyva (obinutuzumab) could eventually more than replace its lucrative but mature Rituxan(rituximab … |
Mushrooms shown to help in fighting cancermySteinbach.ca (blog)There is also an early phase study being conducted on young patients to determine whether beta glucan can increase the effectiveness of rituximab, a drug used in treating some types of lymp…
|
Patents, biosimilars and trademarks – another triangle?
Lexology (registration) Although Roche was taking steps to use Emcure Pharmaceuticals in India “to produce its innovative biologics in India” and to reduce the price for cancer drugs trastuzumab (Herceptin) and rituximab (MabThera), in a surprising but strategic move, Roche … |
Experts Praise Drug Trial for Creating a Realistic Study PopulationMonthly Prescribing ReferenceResearchers compared the benefits of obinutuzumab with that of another antibody rituximab, which also attacks CD20. Both drugs were combined with the chemot…
Medscape |
Mantle Cell Lymphoma — Still More Questions Than Answers
Medscape Expression of Ki-67, a nuclear protein involved in cell proliferation regulation, has been demonstrated to be the most powerful single prognostic factor for overall survival, including in patients treated with rituximab-containing regimens. “If the Ki … |
Xencor Inc.: Current Biotech Uncertainty Is An OpportunitySeeking AlphaPrevious drugs such as Rituximab or Rituxan (Biogen (BIIB) and Roche/Genentech) have also targeted B-cells in RA but have safety issues due to excessive B-cell depletion. However, i…
Experts praise drug trial for building a realistic study populationOncology Nurse AdvisorResearchers compared the benefits of obinutuzumab with that of another antibody rituximab, which also attacks CD20. Both drugs were combined with the chemotherapy …